|
93 Companies |
|
118 Products |
|
118 Products |
|
88 Mechanisms of Action |
|
3 Trials |
|
1622 News |
|
| «12...21222324252627282930313233» |
- ||||| Trial initiation date: B. Lactis HN019 for Functional Constipation (clinicaltrials.gov) - Oct 28, 2012
P3, N=228, Active, not recruiting, Sponsor: Fonterra Research Centre
Initiation date: Dec 2011 --> Mar 2012
- Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Trial completion: Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder (clinicaltrials.gov) - Oct 28, 2012
P3, N=50, Completed, Sponsor: Lindner Center of HOPE
Initiation date: Dec 2011 --> Mar 2012 Recruiting --> Completed
- Enrollment change: Cognitive Behavior Therapy for Adolescents With Bulimia (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=8, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed N=40 --> 8
- Trial completion: Food Exposure Therapy in Anorexia Nervosa (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=32, Completed, Sponsor: New York State Psychiatric Institute
N=40 --> 8 Suspended --> Completed
- Enrollment closed: Inpatient Exposure Therapy and Response Prevention & Cognitive Remediation Therapy for Anorexia Nervosa (clinicaltrials.gov) - Oct 23, 2012
P=N/A, N=30, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Suspended --> Completed Recruiting --> Active, not recruiting
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment change: Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=55, Completed, Sponsor: Henry C. Lin, MD
Recruiting --> Active, not recruiting N=120 --> 55
- |||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Enrollment open: DEFLECT-1: Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) (clinicaltrials.gov) - Oct 21, 2012
P3, N=350, Recruiting, Sponsor: Optimer Pharmaceuticals
N=120 --> 55 Not yet recruiting --> Recruiting
- Enrollment open: Engaging Latino Families in Eating Disorders Treatment (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=40, Recruiting, Sponsor: Mae Lynn Reyes-Rodriguez, PhD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion: Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=55, Completed, Sponsor: Henry C. Lin, MD
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion: Octreotide in Severe Polycystic Liver Disease (clinicaltrials.gov) - Oct 21, 2012
P2/3, N=42, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed
- recanaclotide (IW-9179) / Ironwood Pharma
New P2 trial: Phase 2a Study of IW-9179 to Treat Functional Dyspepsia (clinicaltrials.gov) - Oct 21, 2012
P2, N=10, Terminated, Sponsor: Ironwood Pharmaceuticals, Inc.
- Trial initiation date: Adhesiolysis in Chronic Abdominal Pain (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=0, Withdrawn, Sponsor: North Karelia Central Hospital
Active, not recruiting --> Completed Initiation date: Jan 2013 --> Jan 2014
- Trial withdrawal, Surgery: Overnight Use of Electroacustimulation on Postoperative Nausea and Vomiting in the Outpatient Surgery Population (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Wisconsin, Madison
Initiation date: Jan 2013 --> Jan 2014 Recruiting --> Withdrawn
- Enrollment change, Surgery: Overnight Use of Electroacustimulation on Postoperative Nausea and Vomiting in the Outpatient Surgery Population (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Wisconsin, Madison
Recruiting --> Withdrawn N=100 --> 0
- | dronabinol oral / Generic mfg.
Trial completion: A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas (clinicaltrials.gov) - Oct 14, 2012
P1, N=33, Completed, Sponsor: Duke University
N=100 --> 0 Active, not recruiting --> Completed
- ||||| Trial initiation date: SB-IBS: Saccharomyces Boulardii in Irritable Bowel Syndrome (clinicaltrials.gov) - Oct 13, 2012
P3, N=72, Completed, Sponsor: Aga Khan University
Active, not recruiting --> Completed Initiation date: Jan 2008 --> Jan 2010
- ||||||| Trial completion: SB-IBS: Saccharomyces Boulardii in Irritable Bowel Syndrome (clinicaltrials.gov) - Oct 13, 2012
P3, N=72, Completed, Sponsor: Aga Khan University
Initiation date: Jan 2008 --> Jan 2010 Not yet recruiting --> Completed
- | Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
Trial completion: Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol (clinicaltrials.gov) - Oct 9, 2012
P1, N=42, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment open: WASHB-Kenya: WASH Benefits Kenya (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=8000, Recruiting, Sponsor: Innovations for Poverty Action
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Emestop (ramosetron hydrochloride) / Samyang Group
Trial completion, CINV: Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin (clinicaltrials.gov) - Oct 7, 2012
P2, N=89, Completed, Sponsor: Samsung Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- ||||||| Trial completion: Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment. (clinicaltrials.gov) - Oct 3, 2012
P3, N=96, Completed, Sponsor: Sanofi
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | lignocaine / Generic mfg.
New P4 trial, Surgery: A Study to Assess Analgesic Efficacy of Intravenous Lignocaine (clinicaltrials.gov) - Oct 2, 2012
P4, N=134, Completed, Sponsor: Jawaharlal Institute of Postgraduate Medical Education & Research
- granisetron transdermal (SyB-0701) / Synmosa Biopharma, SymBio Pharma, Abeille Pharma
New P2 trial: Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV) (clinicaltrials.gov) - Oct 2, 2012
P2, N=0, Recruiting, Sponsor: SymBio Pharmaceuticals
- | Trial completion: PRETEC: The Effect of Probiotics on E. Coli Gastroenteritis (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=40, Completed, Sponsor: NIZO Food Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Enrollment open: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - Sep 30, 2012
P3, N=990, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Trial completion: To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole (clinicaltrials.gov) - Sep 30, 2012
P4, N=101, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| ondansetron intravenous / Generic mfg.
Enrollment change: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV) (clinicaltrials.gov) - Sep 29, 2012
P2, N=131, Completed, Sponsor: Accenture
Recruiting --> Completed N=36 --> 131
- 5-fluorouracil / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=22, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=36 --> 131 N=57 --> 22
- |||||||||| bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
New P3 trial: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Sep 27, 2012
P3, N=1400, Active, not recruiting, Sponsor: Cubist Pharmaceuticals
- 5-fluorouracil / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=22, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=57 --> 22 Active, not recruiting --> Completed
- ||||||| Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
Trial completion: A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation (clinicaltrials.gov) - Sep 27, 2012
P3, N=633, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
Trial completion: Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain (clinicaltrials.gov) - Sep 27, 2012
P3, N=336, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
Trial completion: KODIAC 5: Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation (clinicaltrials.gov) - Sep 27, 2012
P3, N=630, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: Alternative Approaches for Nausea Control (clinicaltrials.gov) - Sep 26, 2012
P2, N=216, Recruiting, Sponsor: University of Rochester
- Enrollment change: Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=8, Completed, Sponsor: Huang, Jeannie, M.D.
Active, not recruiting --> Completed N=30 --> 8
- Trial completion: Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=8, Completed, Sponsor: Huang, Jeannie, M.D.
N=30 --> 8 Recruiting --> Completed
- |||| ondansetron intravenous / Generic mfg.
Trial completion: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV) (clinicaltrials.gov) - Sep 25, 2012
P2, N=131, Completed, Sponsor: Accenture
Recruiting --> Completed Recruiting --> Completed
- ondansetron intravenous / Generic mfg.
Enrollment change: Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy (clinicaltrials.gov) - Sep 23, 2012
P4, N=98, Completed, Sponsor: Hospital for Special Surgery, New York
Recruiting --> Completed N=76 --> 98
- Surgery: MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery (clinicaltrials.gov) - Sep 23, 2012
P=N/A, N=150, Recruiting, Sponsor: Duke University
- Resolor (prucalopride) / J&J, Takeda
New P4 trial: A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation (clinicaltrials.gov) - Sep 23, 2012
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
- ||||||| Trial completion: A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation (clinicaltrials.gov) - Sep 23, 2012
P3, N=300, Completed, Sponsor: Ferring Pharmaceuticals
N=76 --> 98 Active, not recruiting --> Completed
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
New P3 trial: DEFLECT-1: Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) (clinicaltrials.gov) - Sep 20, 2012
P3, N=350, Recruiting, Sponsor: Optimer Pharmaceuticals
- |||| Barhemsys (intravenous amisulpride) / Eagle Pharma
Trial completion: Phase II Proof-of-concept Study of APD421 (clinicaltrials.gov) - Sep 20, 2012
P2, N=51, Completed, Sponsor: Acacia Pharma Ltd
Active, not recruiting --> Completed Recruiting --> Completed
- || Enrollment change: International Multicenter Prospective Transtar Registry (clinicaltrials.gov) - Sep 18, 2012
P=N/A, N=100, Completed, Sponsor: Ethicon Endo-Surgery (Europe) GmbH
Recruiting --> Completed N=1000 --> 100
- ||| Trial completion: International Multicenter Prospective Transtar Registry (clinicaltrials.gov) - Sep 18, 2012
P=N/A, N=100, Completed, Sponsor: Ethicon Endo-Surgery (Europe) GmbH
N=1000 --> 100 Recruiting --> Completed
- ||||| New P2 trial: A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults (clinicaltrials.gov) - Sep 17, 2012
P2, N=60, Completed, Sponsor: Braintree Laboratories
- Trial termination: Domperidone for Relief of Gastrointestinal Disorders (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=42, Terminated, Sponsor: Carle Physician Group
Recruiting --> Completed Active, not recruiting --> Terminated; PI withdrew due to increased responsibilities in clinical department.
- Enrollment change: Domperidone for Relief of Gastrointestinal Disorders (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=42, Terminated, Sponsor: Carle Physician Group
Active, not recruiting --> Terminated; PI withdrew due to increased responsibilities in clinical department. N=80 --> 42
- ||| Clinical: Study of Yili "Changqing" Pro-ABB Yoghurt in the Improvement of Human Gastrointestinal Tract System (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=400, Completed, Sponsor: Inner Mongolia Yili Industrial Group Co., Ltd
- Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma, Sancuso (granisetron) / Solasia
Enrollment open: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=39, Recruiting, Sponsor: University of Southern California
N=80 --> 42 Not yet recruiting --> Recruiting